We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-15.77%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$54.8M
Cap. Flow
+$26.4M
Cap. Flow %
14.57%
Top 10 Hldgs %
55.68%
Holding
69
New
12
Increased
29
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$7.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.5M
3
MDVN
MEDIVATION, INC.
MDVN
+$2.46M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.28M
5
MRK icon
Merck
MRK
+$2.28M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.34M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.78M
3
TSRO
TESARO, Inc.
TSRO
+$1.76M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.59M
5
ESPR
Esperion Therapeutics
ESPR
+$1.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.5%
2 Miscellaneous 40.37%
3 Financials 0.14%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LABU icon
51
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
$241K 0.13%
+186
New +$568K
TLPH icon
52
Talphera
TLPH
$63.8M
$176K 0.1%
2,887
-2,111
-42% -$174K
KPTI icon
53
Karyopharm Therapeutics
KPTI
$44M
$155K 0.09%
+983
New +$263K
ASMB icon
54
Assembly Biosciences
ASMB
$709M
$143K 0.08%
1,250
-4,167
-77% -$733K
XNPT
55
DELISTED
XENOPORT, INC.
XNPT
$139K 0.08%
40,000
-90,000
-69% -$568K
LAB icon
56
Standard BioTools
LAB
$256M
$122K 0.07%
+15,000
New +$236K
ESPR
57
DELISTED
Esperion Therapeutics
ESPR
– –
-15,000
Closed -$1.23M
RARE icon
58
Ultragenyx Pharmaceutical
RARE
$2.59B
– –
-9,000
Closed -$922K
NEPT
59
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
0
– -$1K
ALBO
60
DELISTED
Albireo Pharma Inc
ALBO
– –
-21,667
Closed -$670K
ARRY
61
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-2,000
Closed -$135K
TSRO
62
DELISTED
TESARO, Inc.
TSRO
– –
-30,000
Closed -$1.76M
JUNO
63
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-5,000
Closed -$267K
JUNO
64
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-50
Closed -$49K
OCRX
65
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-186,573
Closed -$709K
RLYP
66
DELISTED
RELYPSA INC COM
RLYP
– –
-18,000
Closed -$596K
RCPT
67
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-28,124
Closed -$5.34M
KBIO
68
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
– –
-93,308
Closed -$358K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opus Point Partners Management held 69 positions worth $181M, up 43% from $126M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $26.4M of net new capital in Q3 2015, opening 12 new positions and adding to 29 existing holdings. Its largest new stake was iShares Biotechnology ETF: 60,000 shares worth $6.07M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $1.78M trimmed.

  • Opus Point Partners Management's largest Q3 2015 buy was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
  • Opus Point Partners Management added most to MEDIVATION, INC. in Q3 2015, an estimated $2.46M increase.
  • Opus Point Partners Management's biggest Q3 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $1.78M.
  • Opus Point Partners Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $5.34M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $181M portfolio in Q3 2015.
  • Opus Point Partners Management opened 12 new positions and closed 12 in Q3 2015.
  • Opus Point Partners Management's portfolio value rose 43% quarter-over-quarter to $181M.

Based on Opus Point Partners Management's 13F filing for Q3 2015, filed 16 Nov 2015.